ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$162.86
+1.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.0B | 3.7B | 2.2B | 1.8B | 1.0B |
| Cost of Revenue | 1.1B | 677.2M | 323.4M | 310.4M | 168.8M |
| Gross Profit | 3.9B | 3.0B | 1.9B | 1.5B | 868.6M |
| Operating Expenses | |||||
| R&D Expense | 1.6B | 1.3B | 1.1B | 1.0B | 883.0M |
| SG&A Expense | 1.3B | 1.2B | 975.5M | 795.6M | 770.7M |
| General & Admin Expense | 989.9M | — | 975.5M | 795.6M | 770.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 190.0K | — | — | — | — |
| Total Operating Expenses | 2.9B | 2.5B | 2.1B | 1.8B | 1.7B |
| Cost and Expenses | 4.0B | 3.2B | 2.4B | 2.1B | 1.8B |
| Operating Income (EBIT) | 977.6M | 501.6M | (176.9M) | (282.2M) | (785.1M) |
| Non-Operating | |||||
| Interest Income | 112.3M | 111.5M | 122.0M | 95.6M | 24.8M |
| Interest Expense | 365.0M | 252.6M | 141.9M | 121.2M | 156.0M |
| Net Interest Income | (252.7M) | (141.2M) | (19.9M) | (25.7M) | (131.2M) |
| Other Non-Op Income/Expense | (121.2M) | (178.4M) | (200.5M) | (151.3M) | (341.9M) |
| Non-Operating Income (excl Interest) | (215.2M) | (74.2M) | 58.6M | 30.1M | 186.0M |
| EBT (Pre-Tax Income) | 856.4M | 323.2M | (377.4M) | (433.5M) | (1.1B) |
| Income Tax Expense | (1.9B) | 9.4M | (99.2M) | 6.7M | 4.2M |
| Bottom Line | |||||
| Net Income | 2.7B | 313.7M | (278.2M) | (440.2M) | (1.1B) |
| Earnings from Cont. Ops | 2.8B | 313.7M | (278.2M) | (440.2M) | (1.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.7B | 313.7M | (278.2M) | (440.2M) | (1.1B) |
| Per Share | |||||
| Basic EPS | $20.38 | $2.39 | ($2.18) | ($3.52) | ($9.30) |
| Diluted EPS | $19.80 | $2.33 | ($2.18) | ($3.52) | ($9.30) |
| Revenue Per Share | $37.46 | $28.35 | $17.61 | $14.64 | $8.53 |
| Shares | |||||
| Basic Shares Outstanding | 133.8M | 131.0M | 127.7M | 124.9M | 121.7M |
| Diluted Shares Outstanding | 138.0M | 134.7M | 127.7M | 124.9M | 121.7M |
| Profitability Metrics | |||||
| EBITDA | 1.2B | 631.4M | (178.8M) | (258.2M) | (926.6M) |
| D&A | 55.4M | 55.7M | 56.7M | 54.1M | 44.5M |
| EBIT | 1.2B | 575.8M | (235.5M) | (312.3M) | (971.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026